Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats

Xenobiotica

Volumn 35, Issue 4, 2005, Pages 305-317

  Kanazu, Takushi ^a   Okamura, Noboru ^a,b   Yamaguchi, Yoshitaka ^a   Baba, Takahiko ^a   Koike, Masahiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bioavailability; First pass metabolism; Intestinal metabolism; Jugular and portal vein double cannulated rat; Ketoconazole; Midazolam; Portal vein

Indexed keywords

CYTOCHROME P450 3A4; DEXAMETHASONE; KETOCONAZOLE; MIDAZOLAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANNULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FIRST PASS EFFECT; INTESTINE ABSORPTION; LIVER METABOLISM; NONHUMAN; PORTAL VEIN BLOOD FLOW; RAT; SYSTEMIC CIRCULATION; XENOBIOTIC METABOLISM;

ANIMALS; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DRUG INTERACTIONS; FEMALE; INTESTINES; KETOCONAZOLE; LIVER; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 20944439899     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500093786     Document Type: Article

References (38)

1. Carrilo JA, Ramos SI, Agundez JAG, Martinez C, Benitez J. 1998. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A. Therapeutic Drug Monitoring 20:319-324.
2. Cooper KO, Reik LM, Jayyoshi Z, Bandiera S, Kelley M, Ryan DE, Daniel R, McCluskey SA, Levin W, Thomas PE. 1993. Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Archives of Biochemistry and Biophysics 301:345-354.
3. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 10:1093-1095
4. Debri K, Boobis AR, Davies DS, Edwards RJ. 1995. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochemical Pharmacology 50:2047-2056.
5. DeWaziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. 1990. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. The Journal of Pharmacology and Experimental Therapeutics 253:387-394.
6. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. 1999. Cytochrome P450 3A: Ontogeny and drug disposition. Clinical Pharmacokinetics 37:485-505.
7. Eeckhoudt SL, Horsmans Y, Verbeeck RK. 2003. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32:975-984.
8. Ghosal A, Sadrieh A, Reik L, Levin W, Thomas PE. 1996b. Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Archives of Biochemistry and Biophysics 332:153-162.
9. Ghosal A, Sato H, Thomas PE, Bush E, Moore D. 1996a. Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition 24:940-947.
10. Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ. 2003. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: In vitro metabolism and pharmacokinetics of midazolam. Drug Metabolism and Disposition 31:548-558.
11. Guengerich FP. 1999. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology 39:1-17.
12. Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS. 1982. Purification and characterization of liver microsomal cytochromes P-450: Electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphtoflavone. Biochemistry 21:6019-6030.
13. Higashikawa F, Murakami T, Kaneda T, Kato A, Takano M. 1999. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. Journal of Pharmacy and Pharmacology 51:67-72.
14. Ishigami M, Kawabata K, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. 2001. Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metabolism and Disposition 29:1068-1072.
15. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacological Reviews 50:387-411.
16. Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M. 2004a. A model for the drug-drug interaction responsible for CYP3A enzyme inhibition: I. evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 35:391-402.
17. Kanazu T, Yamaguchi Y, Okamura N, Baba T, Koike M. 2004b. A model for the drug-drug interaction responsible for CYP3A enzyme inhibition: II. Establishment and evaluation of dexamethasone pretreated female rats. Xenobiotica 34:403-415.
18. Kotegawa T, Laurijssens BE, von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan KV, Warrington JS, Granda BW, Harmatz JS, Greenblatt DJ. 2002. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. The Journal of Pharmacology and Experimental Therapeutics 302:1228-1237.
19. Kremers P. 2002. Can drug-drug interactions be predicted from in vitro studies? The Scientific World Journal 2:751-766.
20. Kuperman AV, Kalgutkar AS, Marfat A, Chambers R, Liston T. 2001. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: In vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue. Drug Metabolism and Disposition 29:1403-1409.
21. Kuroha M, Azumano A, Kuze Y, Shimoda M, Kokue E. 2002. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metabolism and Disposition 30:63-68.
22. Lin JH, Chiba M, Chen IW, Nishime JA, Deluna FA, Yamazaki M, Lin YJ. 1999. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction. Drug Metabolism and Disposition 27:1187-1193.
23. Matsubara T, Otsubo S, Yoshihara E. 1983. Liver microsomal cytochrome P-450-dependent O-dealkylation reaction in various animals. Japanese Journal of Pharmacology 33:1065-1075.
24. Murakami T, Nakanishi M, Yoshimori T, Okamura N, Norikura R, Mizojiri K. 2003. Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metabolism and Pharmacokinetics 18:252-260.
25. Nakamura A, Hirota T, Morino A, Imaoka S, Funae Y, Yamamoto Y, Tasaki T, Masuda M, Kazusaka A, Fujita S. 1999. Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21. Xenobiotica 29:243-252.
26. Obach RS, Zhang QZ, Dunbar D, Kaminsky LS. 2001. Metabolic characterization of the major human small intestinal cytochrome P450s. Drug Metabolism and Disposition 29:347-352.
27. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. 1997. Characterization of inter- and intra-intestinal differences in human CYP3A-dependent metabolism. The Journal of Pharmacology and Experimental Therapeutics 283:1552-1562.
28. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. 1996. First-pass metabolism of midazolam by the human intestine. Clinical Pharmacology and Therapeutics 60:14-24.
29. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP. 1997. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition 25:1191-1199.
30. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of Pharmacology and Experimental Therapeutics 270:414-423.
31. Thummel KE, Kunze KL, Shen DD. 1996a. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Advanced Drug Delivery Reviews 27:99-127.
32. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Oerkins JD, Wilkinson GR. 1996b. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics 59:491-502.
33. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL. 1994b. Use of midazolam as a human cytochrome P450 3A probe: II. characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. The Journal of Pharmacology and Experimental Therapeutics 271:557-566.
34. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL. 1994a. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. The Journal of Pharmacology and Experimental Therapeutics 271:549-556.
35. Uhing MR, Beno DWA, Jiyamapa-Serna VA, Chen Y, Galinsky RE, Hall SD, Kimura RE. 2004. The effect of anesthesia and surgery on CYP3A activity in rats. Drug Metabolism and Disposition 32:1325-1330.
36. Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE. 1990. In vitro and in vivo biotransformation of simvastatin, and inhibitor of HMG-CoA reductase. Drug Metabolism and Disposition 18:476-483.
37. Watkins PB, Wrighton SA, Schuetz EG, Guzelian PS. 1987. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. Journal of Clinical Investigation 80:1029-1036.
38. Yuasa H, Matsuda K, Watanabe J. 1993. Influence of anesthetic regimens on intestinal absorption in rats. Pharmaceutical Research 10:884-888.